Europe Cancer Immunotherapy Market to 2032
Overview
The Europe Cancer Immunotherapy Market is expected to reach a 50.47 USD Billion by 2032 and is projected to grow at a CAGR of 15.89% from 2025 to 2032.
Revenue, 2024 (USD Billion)
20.12
Forecast, 2032 (USD Billion)
50.47
CAGR, 2024 - 2032
15.89%
Report Coverage
Europe
Europe Cancer Immunotherapy Market 2018-2032 USD Billion
Europe Cancer Immunotherapy Market, Key Findings (2025-2032)
Market Growth and Projections:
- Market Size (2024): 20.12 USD Billion
- Projected Market Size (2032): 50.47 USD Billion
- CAGR (2025-2032): 15.89%
Key Findings of Europe Cancer Immunotherapy Market
- The Europe Cancer Immunotherapy Market was valued at 20.12 USD Billion in 2024.
- The Europe Cancer Immunotherapy Market is likely to grow at a CAGR of 15.89% during the forecast period of 2024 to 2032.
- In 2024, the Largest segment Intravenous (IV) in Form Segment accounted for the largest share of the market with a revenue of 18.14 USD Billion
- The fastest growing segment Lung Cancer in Application Segment grew Fastest with a CAGR of 20.67% during the forecast period from 2024 to 2032.
Europe Cancer Immunotherapy Market Scope
Europe Cancer Immunotherapy Market Segmentation & Scope
Application
- Prostate Cancer
- Ovarian Cancer
- Cervical Cancer
- Stomach Cancer
- Multiple Myeloma
- Lung Cancer
- Breast Cancer
- Melanoma
- Colorectal Cancer
- Head & Neck Cancer
- Others
Product
- Cell Therapies
- Immunomodulators
- Oncolytic Virus
- Vaccines
- Checkpoint Inhibitors
- Monoclonal Antibodies
Distribution Channel
- Pharmacies
- Retail Sales
- Direct Tenders
End User
- Hospitals
- Oncology Clinics
- Homecare
- Others
Form
- Intravenous (IV)
- Intramuscular
- Oral
Europe Cancer Immunotherapy Market Data Coverage Insights
| Study Period | 2024-2032 |
| Base Year | 2021 |
| Unit | Revenue in USD Billion |
| Market Value in 2024 | 20.12 USD Billion |
| Market Value in 2032 | 50.47 USD Billion |
| CAGR (2025-2032) | 15.89% |
| Historic Data | 2016-2023 |
| Market Segments Covered | Application,Product,Distribution Channel,End User,Form |
Regional Insights:
-
Leading Market (2024-2032): Europe, leading in terms of revenue 20.12 USD Billion in 2024
- Key Country: Austria, leading in terms of revenue with value of 408.55 USD Million in 2024.
Segments and Scope
-
Europe Cancer Immunotherapy Market to 2032, By Application
- Lung Cancer is the largest segment in Europe Cancer Immunotherapy Market to 2032 with a revenue of 4.00 USD Billion in the year 2024.
- Lung Cancer is the Fastest growing segment in Europe Cancer Immunotherapy Market to 2032 with a Growth rate of 20.67 % in forecast period 2025-2032.
-
Europe Cancer Immunotherapy Market to 2032, By Product
- Checkpoint Inhibitors is the largest segment in Europe Cancer Immunotherapy Market to 2032 with a revenue of 13.19 USD Billion in the year 2024.
- Checkpoint Inhibitors is the Fastest growing segment in Europe Cancer Immunotherapy Market to 2032 with a Growth rate of 16.10 % in forecast period 2025-2032.
-
Europe Cancer Immunotherapy Market to 2032, By Distribution Channel
- Direct Tenders is the largest segment in Europe Cancer Immunotherapy Market to 2032 with a revenue of 13.11 USD Billion in the year 2024.
- Direct Tenders is the Fastest growing segment in Europe Cancer Immunotherapy Market to 2032 with a Growth rate of 16.47 % in forecast period 2025-2032.
-
Europe Cancer Immunotherapy Market to 2032, By End User
- Hospitals is the largest segment in Europe Cancer Immunotherapy Market to 2032 with a revenue of 13.51 USD Billion in the year 2024.
- Hospitals is the Fastest growing segment in Europe Cancer Immunotherapy Market to 2032 with a Growth rate of 16.03 % in forecast period 2025-2032.
-
Europe Cancer Immunotherapy Market to 2032, By Form
- Intravenous (IV) is the largest segment in Europe Cancer Immunotherapy Market to 2032 with a revenue of 18.14 USD Billion in the year 2024.
- Intravenous (IV) is the Fastest growing segment in Europe Cancer Immunotherapy Market to 2032 with a Growth rate of 15.98 % in forecast period 2025-2032.
Europe Cancer Immunotherapy Market Company Share Analysis
| Company Name |
|
||
| Merck & Co., Inc. | |||
| Janssen Pharmaceuticals, Inc. | |||
| Bristol-Myers Squibb Company | |||
| AstraZeneca | |||
| Gilead Sciences, Inc. | |||
Europe Cancer Immunotherapy Market Geographical Sales Distribution, 2018-2032 USD Billion
Europe Cancer Immunotherapy Market Company Profiling
Industry Related Reports
Frequently Asked Questions
The Europe Cancer Immunotherapy Market is segmented based on Segmentation Application,Product,Distribution Channel,End User,Form.
Europe Cancer Immunotherapy Market was valued at USD 20.12(Revenue in USD Billion) in 2021.
Europe Cancer Immunotherapy Market is projected to grow at a CAGR of 15.89% during the forecast period of 2024 to 2032.
The Intravenous (IV) segment is expected to dominate the Europe Cancer Immunotherapy Market, holding a largest market share of 18.14 USD Billion in 2024
Europe Cancer Immunotherapy Market Scope
Europe Cancer Immunotherapy Market Segmentation & Scope
Application
- Prostate Cancer
- Ovarian Cancer
- Cervical Cancer
- Stomach Cancer
- Multiple Myeloma
- Lung Cancer
- Breast Cancer
- Melanoma
- Colorectal Cancer
- Head & Neck Cancer
- Others
Product
- Cell Therapies
- Immunomodulators
- Oncolytic Virus
- Vaccines
- Checkpoint Inhibitors
- Monoclonal Antibodies
Distribution Channel
- Pharmacies
- Retail Sales
- Direct Tenders
End User
- Hospitals
- Oncology Clinics
- Homecare
- Others
Form
- Intravenous (IV)
- Intramuscular
- Oral
Frequently Asked Questions
The Europe Cancer Immunotherapy Market is segmented based on Segmentation Application,Product,Distribution Channel,End User,Form.
Europe Cancer Immunotherapy Market was valued at USD 20.12(Revenue in USD Billion) in 2021.
Europe Cancer Immunotherapy Market is projected to grow at a CAGR of 15.89% during the forecast period of 2024 to 2032.
The estimated market value of the Europe Cancer Immunotherapy Market for final year is USD 50.47 (USD Billion).
Europe Cancer Immunotherapy Market Company Profiling
Frequently Asked Questions
The Europe Cancer Immunotherapy Market is segmented based on Segmentation Application,Product,Distribution Channel,End User,Form.
Europe Cancer Immunotherapy Market was valued at USD 20.12(Revenue in USD Billion) in 2021.
Europe Cancer Immunotherapy Market is projected to grow at a CAGR of 15.89% during the forecast period of 2024 to 2032.
The estimated market value of the Europe Cancer Immunotherapy Market for final year is USD 50.47 (USD Billion).
HAVE A QUESTION?
Get expert advice on the right strategy for your business at no cost. We also offer customized subscription plans and affordable discounts for startups and universities.